ArticleScientific reports2025
A computational approach to mycolic acid biosynthesis disruption in mycobacterium tuberculosis via molluscan metabolites as KasA inhibitors.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Structure-Based Virtual Screening of Natural Product-Derived Inhibitors Targeting Rv3806c in the Decaprenylphosphoryl-d-Arabinose Biosynthetic Pathway ofInternational journal of molecular sciences · 2026Article
- Breaking the barrier: from biosynthetic inhibition to multidimensional modulation of the mycobacterial cell wall in tuberculosis therapy.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ongoing global health challenge posed by Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is exacerbated by the emergence of drug-resistant strains. This study explores the potential of inhibiting the KasA protein, a key component of the bacterium's type II fatty acid synthase system (FAS-II) involved in mycolic acid biosynthesis. Inhibition of KasA could disrupt the integrity of the mycobacterial cell wall, which is crucial for its survival and virulence. In this study, we screened a library of 730 Molluscan metabolites using molecular docking techniques via the Glide tool, identifying ten compounds with significant binding affinities ranging from - 7.535 to -6.517 kcal/mol. The ADMET profiles of these compounds were evaluated, revealing acceptable toxicity levels for four selected candidates: CMNPD7125, CMNPD22991, CMNPD4542, and CMNPD12265. Additionally, molecular dynamics simulations confirmed the stability of these compounds within the KasA binding pocket, reinforcing their potential as effective inhibitors. This integrated approach combining molecular docking, ADMET analysis, and dynamic simulations advances the search for innovative treatments against drug-resistant TB and supports rational drug design efforts for future anti-tubercular agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.